β
Outcome MeasureQuality of Life

EQ-5D-3L

EuroQol 5-Dimension 3-Level

1 Paper in Blossom

Clinical Thresholds

-0.591
Worse than dead
Score -1–0
Impaired QoL
Score 0–0
Good QoL
Score 1–1

Outcome Data Across Studies

Reported results for EQ-5D-3L across 1 study with quantitative data.

Outcome data across 2 study arm–timepoint observations
SD
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
2023Exploratory
25 mg COMP360(experimental)0190.50.3—
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
2023Exploratory
25 mg COMP360(experimental)21190.2Δ0.3—

Papers Using EQ-5D-3L

Open Accessindividual

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication

This open-label Phase II trial (n=19) investigates the safety, tolerability, and efficacy of synthetic psilocybin (COMP360) as an adjunct to selective serotonin reuptake inhibitors (SSRIs) in adults with treatment-resistant depression (TRD). The study found no serious treatment-emergent adverse events or increased suicidal ideation. It reported a significant decrease in depression (MADRS) and Clinical Global Impression-Severity (CGI-S) scores at week 3, with response and remission observed in 42.1% of participants.

Published
Journal
Neuropharmacology
Authors
Goodwin, G. M., Croal, M., Feifel, D., Kelly, J. R., Marwood, L., Mistry, S., O'keane, V., Peck, S. K., Simmons, H., Sisa, C., Stansfield, S. C., Tsai, J., Williams, S., Malievskaia, E.

Quick Facts

Full Name
EuroQol 5-Dimension 3-Level
Domain
Quality of Life
Papers Indexed
1
Score Range
-0.59–1
Interpretation
Higher = better
Unit
utility index
Reference
Visit
All Measures